PrintThe BIO International Convention that just concluded in Chicago can be described in many ways. On one hand it was a gathering of nearly 15,000 industry leaders looking to discuss evolving business models, ongoing policy issues, and the changing financial landscape. On the other hand, it was a bit like a continuous speed dating session spread over four days, an oversized convention facility, a few dozen hotels, as well as busses, bars, and parties. This week we’re departing from our usual format to give our listeners a taste of the convention with the voices from a few of the folks we met during our stay in the Windy City. What you’ll hear is a diverse group of people who are excited by innovative ideas, optimistic about the future, and ready to find partners with which to work.
DEALMAKING
Let's Make a Deal
Podcast May 10, 2010The Burrill Report (May 10, 2010): Let's Make a Deal (.MP3,11.96 Mb)
The BIO International Convention that just concluded in Chicago can be described in many ways. On one hand it was a gathering of nearly 15,000 industry leaders looking to discuss evolving business models, ongoing policy issues, and the changing financial landscape. On the other hand, it was a bit like a continuous speed dating session spread over four days, an oversized convention facility, a few dozen hotels, as well as busses, bars, and parties. This week we’re departing from our usual format to give our listeners a taste of the convention with the voices from a few of the folks we met during our stay in the Windy City. What you’ll hear is a diverse group of people who are excited by innovative ideas, optimistic about the future, and ready to find partners with which to work.
The BIO International Convention that just concluded in Chicago can be described in many ways. On one hand it was a gathering of nearly 15,000 industry leaders looking to discuss evolving business models, ongoing policy issues, and the changing financial landscape. On the other hand, it was a bit like a continuous speed dating session spread over four days, an oversized convention facility, a few dozen hotels, as well as busses, bars, and parties. This week we’re departing from our usual format to give our listeners a taste of the convention with the voices from a few of the folks we met during our stay in the Windy City. What you’ll hear is a diverse group of people who are excited by innovative ideas, optimistic about the future, and ready to find partners with which to work.
[Please login to post comments]
- Sanofi Complains About Canada's Bias for Generics As It Cuts Jobs
Company takes issue with lack of sufficient intellectual property protection. Read More - InterMune's Terrible, Horrible, No Good, Very Bad Day
FDA says it wants another trial before it will approve experimental drug for fatal lung disease. Read More - Wondering About A Potential Wonder Drug
GSK suspends trial of Sirtris’ experimental therapy. Read More - Ariad’s New Deal
Revised agreement with Merck refills biotech’s coffers. Read More - J&J; Unit Announces Voluntary Recall of Over-the Counter Kid's Drugs
The weekly round-up of failed trials, missed targets and other business mishaps. Read More - A Bright Spot in the Economy
Bioscience jobs show some growth despite recession. Read More - A Caregiver’s Toll
The stress of taking care of a partner with dementia boosts likelihood of a spouse developing the same condition. Read More - A New Super Detective
New technology identifies bacteria, viruses, other organisms within 24 hours. Read More - Medtech Brings in Life Sciences Venture Dollars
The weekly wrap-up of financings and deals. Read More - Surviving in a Changing Environment
Podcast: May 3, 2010 Read More
.gif)
- Exclusive: Obscure biotech Regeneron on verge of big league
Reuters - FDA to look into gene tests to be sold at Walgreen
Reuters - Walgreen Stores to Sell Spit-and-Mail Gene Testing Kits in U.S.
Bloomberg - Merck to Seek U.S. Approval for 5 New Drugs in 2010
Bloomberg - New Obama Strategy Treats ‘War’ on Drugs as Public Health Issue
Bloomberg - Memo to boss: 11-hour days are bad for the heart
Reuters - Florida Suit Poses a Challenge to Health Care Law
The New York Times - Glaxo Said to Pay $60 Million in Avandia Settlements
Bloomberg - Keeping Junior on Parent’s Insurance Is a Tax Benefit
Bloomberg - Payment Offers to Egg Donors Prompt Scrutiny
The New York Times